Company Analysis

Parabilis Medicines, Inc. (PBLS)

Nasdaq: PBLS · Pharmaceutical Preparations · filing with the SEC since 2015
Grade5.8
◀ Past 6.0● Present 6.5▶ Future 5.0
8 est.
The companyas filed
Revenuen/a
Net incomen/a
Earnings per sharen/a
Operating cash flown/a
Cashn/a
Debtn/a
Shareholders’ equityn/a
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202658
Newest filingNov 12 · 10-Q
Annual reportn/a
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$431M
Patents granted3
Filer category<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
The record holds no annual figures yet.
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 12, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 15, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 2, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 25, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 25, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 14, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Aug 13, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton PBLS · research, not advice